We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+5.71%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$2.65B
AUM Growth
-$277M
Cap. Flow
+$27.9M
Cap. Flow %
1.06%
Top 10 Hldgs %
67.67%
Holding
75
New
11
Increased
7
Reduced
10
Closed
16

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$94.4M
2
SWTX
SpringWorks Therapeutics
SWTX
+$54.5M
3
QURE icon
uniQure
QURE
+$29.4M
4
ZYME icon
Zymeworks
ZYME
+$22.2M
5
XNCR icon
Xencor
XNCR
+$18.7M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$51.5M
2
VRDN icon
Viridian Therapeutics
VRDN
+$44.6M
3
NUVB icon
Nuvation Bio
NUVB
+$44M
4
PCVX icon
Vaxcyte
PCVX
+$40.3M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$33.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBIO
51
DELISTED
Generation Bio
GBIO
$2.17M 0.08%
204,687
– –
PRME icon
52
Prime Medicine
PRME
$535M
$2.04M 0.08%
700,000
– –
ETON icon
53
CALL
Eton Pharmaceutcials
ETON
$1.31B
$2.02M 0.08%
151,400
-76,600
-34% -$777K
WHWK
54
Whitehawk Therapeutics
WHWK
$181M
$1.09M 0.04%
345,253
-1,500,000
-81% -$3.4M
UPB
55
Upstream Bio Inc
UPB
$343M
$986K 0.04%
+60,000
New +$1.34M
SRZNW icon
56
Surrozen Inc Warrant
SRZNW
$36.6K
$957K 0.04%
66,665
– –
HOOK
57
DELISTED
HOOKIPA Pharma
HOOK
$782K 0.03%
388,861
-182,866
-32% -$566K
ARTV
58
Artiva Biotherapeutics
ARTV
$493M
$418K 0.02%
41,453
– –
GLUE icon
59
CALL
Monte Rosa Therapeutics
GLUE
$1.83B
$151K 0.01%
+21,700
New +$163K
ALLK
60
DELISTED
Allakos
ALLK
– –
-192,346
Closed -$126K
BBIO icon
61
BridgeBio Pharma
BBIO
$16.5B
– –
-170,172
Closed -$4.33M
CLDX icon
62
Celldex Therapeutics
CLDX
$2.82B
– –
-650,000
Closed -$22.1M
CNTA
63
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-3,223,851
Closed -$51.5M
EWTX icon
64
Edgewise Therapeutics
EWTX
$4.23B
– –
-1,250,385
Closed -$33.4M
IONS icon
65
Ionis Pharmaceuticals
IONS
$9.07B
– –
-500,000
Closed -$20M
ITOS
66
DELISTED
iTeos Therapeutics
ITOS
– –
-1,608,616
Closed -$16.4M
MGNX icon
67
MacroGenics
MGNX
$235M
– –
-56,018
Closed -$184K
NUVB icon
68
Nuvation Bio
NUVB
$2.26B
– –
-19,209,643
Closed -$44M
PCVX icon
69
Vaxcyte
PCVX
$7.64B
– –
-352,464
Closed -$40.3M
PHVS icon
70
Pharvaris
PHVS
$2.28B
– –
-900,000
Closed -$16.7M
PRQR icon
71
ProQR Therapeutics
PRQR
$243M
– –
-1,835,991
Closed -$3.34M
VRDN icon
72
Viridian Therapeutics
VRDN
$2.14B
– –
-1,958,847
Closed -$44.6M
KYTX icon
73
Kyverna Therapeutics
KYTX
$429M
– –
-450,000
Closed -$2.2M
LENZ
74
LENZ Therapeutics
LENZ
$178M
– –
-346,772
Closed -$8.23M
CMAXW
75
DELISTED
CareMax, Inc. Warrant
CMAXW
– –
-100,000
Closed -$170K
1 2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q4 2024 Portfolio in Review

As of Q4 2024, EcoR1 Capital held 75 positions worth $2.65B, down 9.5% from $2.92B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

EcoR1 Capital's Q4 2024 filing shows 11 new, 7 increased, 10 reduced and 16 closed positions. Its largest new stake was Sarepta Therapeutics: 770,000 shares worth $93.6M. The largest sale was Centessa Pharmaceuticals, an estimated $51.5M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier.

  • EcoR1 Capital's largest Q4 2024 buy was Sarepta Therapeutics: 770,000 shares worth $93.6M.
  • EcoR1 Capital added most to Zymeworks in Q4 2024, an estimated $22.2M increase.
  • EcoR1 Capital's biggest Q4 2024 reduction was Kura Oncology, cutting an estimated $32.4M.
  • EcoR1 Capital fully exited Centessa Pharmaceuticals in Q4 2024, selling an estimated $51.5M.
  • EcoR1 Capital's ten largest holdings make up 68% of its $2.65B portfolio in Q4 2024.
  • EcoR1 Capital opened 11 new positions and closed 16 in Q4 2024.
  • EcoR1 Capital's portfolio value fell 9.5% quarter-over-quarter to $2.65B.

Based on EcoR1 Capital's 13F filing for Q4 2024, filed 14 Feb 2025.